Therefore, optimal efficacy in these models correlated with an increase in activated, memory and proliferating CD4+ and CD8+ T cells in the blood, TDLNs and tumor, an increase in cytotoxic NK cells and a reduction in Treg and exhausted CD8+ T cells in the tumor microenvironment (TME). The gene discussed is CD8A; the disease is neoplasm.